Processing and presentation of tumor antigens and vaccination strategies

Current Opinion in Immunology

Volumn 18, Issue 1, 2006, Pages 98-104

  Bruggen, Pierre Van Der ^a   Eynde, Benoît J Van Den ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEASOME; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; AUTOPHAGY; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PROTEIN BINDING; REVIEW; VACCINATION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 30044438884     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2005.11.013     Document Type: Review

References (57)

1. Van den Eynde B, van der Bruggen P: Peptide database of T-cell defined tumor antigens. URL: http://www.cancerimmunity.org/peptidedatabase/ Tcellepitopes.htm.
2. U. Schubert, L.C. Anton, J. Gibbs, C.C. Norbury, J.W. Yewdell, and J.R. Bennink Rapid degradation of a large fraction of newly synthesized proteins by proteasomes Nature 404 2000 770 774
3. M.F. Princiotta, D. Finzi, S.B. Qian, J. Gibbs, S. Schuchmann, F. Buttgereit, J.R. Bennink, and J.W. Yewdell Quantitating protein synthesis, degradation, and endogenous antigen processing Immunity 18 2003 343 354
4. K. Hanada, J.W. Yewdell, and J.C. Yang Immune recognition of a human renal cancer antigen through post-translational protein splicing Nature 427 2004 252 256 This study provided the first example of an antigenic peptide produced by splicing. The authors identified the peptide recognized by human CTLs directed against a renal cell carcinoma. They show that the peptide, which is derived from FGF5, is not encoded as such by the FGF5 gene but is made by the fusion of a five-residue fragment with a four-residue fragment that is located 40 residues away. The authors excluded RNA splicing and ribosome skipping as mechanisms potentially responsible for the production of this peptide, and conclude that it results from a post-translational modification that entails the excision of the intervening segment of 40 amino acids and the ligation of the two fragments. This is the first example of protein or peptide splicing in vertebrates. The mechanism has not been elucidated.
5. N. Vigneron, V. Stroobant, J. Chapiro, A. Ooms, G. Degiovanni, S. Morel, P. van der Bruggen, T. Boon, and B.J. Van den Eynde An antigenic peptide produced by peptide splicing in the proteasome Science 304 2004 587 590 This was the second example of an antigenic peptide produced by peptide splicing. Here, the parent protein is gp100, a melanocytic protein, and the peptide is recognized by human CTLs directed against melanoma. The peptide is made by the splicing of two segments initially separated by four residues. The authors show that the splicing of this peptide is catalyzed by the proteasome, and appears to occur by reverse proteolysis (Figure 1). Such a mechanism implies that splicing, although inefficient, is not uncommon and is likely to increase the diversity of antigenic peptides presented by MHC class I molecules.
6. B. Meusser, C. Hirsch, E. Jarosch, and T. Sommer ERAD: the long road to destruction Nat Cell Biol 7 2005 766 772
7. E.J. Wiertz, D. Tortorella, M. Bogyo, J. Yu, W. Mothes, T.R. Jones, T.A. Rapoport, and H.L. Ploegh Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction Nature 384 1996 432 438
8. E. Godefroy, A. Moreau-Aubry, E. Diez, B. Dréno, F. Jotereau, and Y. Guilloux αvβ3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen J Exp Med 202 2005 61 72 The authors describe an antigenic peptide derived from MMP2. The presentation of this peptide on class I molecules by human melanoma cells requires actual secretion of MMP2 by melanoma cells in the extracellular space, followed by uptake of exogenous MMP2 through endocytosis mediated by integrin αVβ3, which functions as a receptor for MMP2. This implies a cross-presentation mechanism in melanoma cells. Most surprising is the fact that this MMP2 peptide was found not to be processed by the classical endogenous processing pathway relying on ERAD [ 6,7 ], because melanoma cells expressing MMP2 but not αVβ3 do not present the peptide.
9. L. Chapatte, C. Servis, D. Valmori, O. Burlet-Schiltz, J. Dayer, B. Monsarrat, P. Romero, and F. Lévy Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells J Immunol 173 2004 6033 6040
10. 209-217T210M Cancer Immunol Immunother 53 2004 817 824
11. A.K. Nussbaum, T.P. Dick, W. Keilholz, M. Schirle, S. Stevanovic, K. Dietz, W. Heinemeyer, M. Groll, D.H. Wolf, and R. Huber Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1 Proc Natl Acad Sci USA 95 1998 12504 12509
12. S. Vijayasaradhi, Y. Xu, B. Bouchard, and A.N. Houghton Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75 J Cell Biol 130 1995 807 820
13. P. van der Bruggen, Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E.S. Schultz, J. Chapiro, B.J. Van den Eynde, F. Brasseur, and T. Boon Tumor-specific shared antigenic peptides recognized by human T cells Immunol Rev 188 2002 51 64
14. C. Paludan, D. Schmid, M. Landthaler, M. Vockerodt, D. Kube, T. Tuschl, and C. Munz Endogenous MHC class II processing of a viral nuclear antigen after autophagy Science 307 2005 593 596 Some tumors express class II molecules and present to CD4+ T cells peptides derived from cytosolic or nuclear proteins. How these proteins reach the endocytic compartment has been unclear. Here, the authors show that Epstein-Barr virus nuclear antigen 1 (EBNA-1) reaches the class II processing pathway by autophagy, an intracellular process whereby cytoplasmic material is enveloped into double-membrane vesicles, which then fuse with lysosomes. Inhibition of lysosomal acidification resulted in the accumulation of EBNA-1 in cytosolic autophagosomes. Inhibition of autophagy decreased recognition by EBNA-1-specific CD4+ T cell clones. Contrary to the class-I presentation pathway, which favors short-lived substrates, this 'internal' class II pathway appears to preferentially process long-lived substrates.
15. •], these results imply a major role of autophagy in the MHC II presentation of peptides derived from intracellular proteins.
16. D. Zhou, P. Li, Y. Lin, J.M. Lott, A.D. Hislop, D.H. Canaday, R.R. Brutkiewicz, and J.S. Blum Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens Immunity 22 2005 571 581 Chaperone-mediated autophagy (CMA) results in the transport of cytosolic proteins directly into late endosomal and lysosomal compartments. The authors demonstrate the involvement of CMA in the presentation of cytoplasmic antigens by MHC class II molecules. By manipulating the expression levels of chaperone hsc70 and Lamp-2a, two proteins involved in CMA, they show that these proteins mediate the transport of cytosolic proteins into endosomal compartments for presentation by MHC class II.
17. W. Chen, K-A. Masterman, S. Basta, Haeryfar SMM, N. Dimopoulos, B. Knowles, J.R. Bennink, and J.W. Yewdell Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon Eur J Immunol 34 2004 194 199
18. A.F. Ochsenbein, S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R.M. Zinkernagel Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction Nature 411 2001 1058 1064
19. R.M. Zinkernagel On cross-priming of MHC class I-specific CTL: rule or exception? Eur J Immunol 32 2002 2385 2392
20. L. Shen, and K.L. Rock Cellular protein is the source of cross-priming antigen in vivo Proc Natl Acad Sci USA 101 2004 3035 3040
21. • ]. Here, the authors show that treating antigenic cells with the proteasome inhibitor lactacystin did not prevent, and even enhanced, their ability to cross-prime. Their results imply that the antigens that are transferred for cross-priming are proteasome substrates and not proteasome digestion products. They also observed that cross-priming is more efficient for long-lived than for short-lived proteins.
22. + T cells Nat Immunol 6 2005 593 599
23. •], this report supports the view that cross-priming occurs via transfer of proteins rather than peptides.
24. J. Hombach, H. Pircher, S. Tonegawa, and R.M. Zinkernagel Strictly transporter of antigen presentation (TAP)-dependent presentation of an immunodominant cytotoxic T lymphocyte epitope in the signal sequence of a virus protein J Exp Med 182 1995 1615 1619
25. T. Wölfel, A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K.-H. Meyer zum Büschenfelde, and T. Boon Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes Eur J Immunol 24 1994 759 764
26. L. Delamarre, M. Pack, H. Chang, I. Mellman, and E.S. Trombetta Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate Science 307 2005 1630 1634 The authors show that, compared with DCs, macrophages contain more lysosomal protease and have a higher proteolytic activity. Accordingly, endocytosed proteins survive longer in DCs compared with macrophages. This longer survival might favor the formation of peptide-MHC II complexes and contribute to the capacity of DCs to cross-present exogenous antigens on MHC class I molecules.
27. P. Guermonprez, L. Saveanu, M. Kleijmeer, J. Davoust, P. van Endert, and S. Amigorena ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells Nature 425 2003 397 402
28. M. Houde, S. Bertholet, E. Gagnon, S. Brunet, G. Goyette, A. Laplante, M.F. Princiotta, P. Thibault, D. Sacks, and M. Desjardins Phagosomes are competent organelles for antigen cross-presentation Nature 425 2003 402 406
29. Y. Wan, Y. Wu, J. Zhou, L. Zou, Y. Liang, J. Zhao, Z. Jia, J. Engberg, J. Bian, and W. Zhou Cross-presentation of phage particle antigen in MHC class II and endoplasmic reticulum marker-positive compartments Eur J Immunol 35 2005 2041 2050
30. N. Touret, P. Paroutis, M. Terebiznik, R.E. Harrison, S. Trombetta, M. Pypaert, A. Chow, A. Jiang, J. Shaw, and C. Yip Quantitative and dynamic assessment of the contribution of the ER to phagosome formation Cell 123 2005 157 170
31. J. Imai, H. Hasegawa, M. Maruya, S. Koyasu, and I. Yahara Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells Int Immunol 17 2005 45 53
32. A.L. Ackerman, C. Kyritsis, R. Tampe, and P. Cresswell Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells Nat Immunol 6 2005 107 113 The authors demonstrate that in DCs, soluble exogenous proteins may enter the lumen of the ER. In a previous study [57], they made the surprising observation that incubating DCs with a soluble fragment of US6, a viral protein that inhibits TAP function, resulted in a reduction of MHC class I molecules at the cell surface, presumably because US6 had accessed the perinuclear ER. Here, they find that exogenous β2m provided to β2m-deficient DCs localizes rapidly to the perinuclear ER, associates with MHC class I heavy chains, reconstitutes cell surface class I expression and normalizes presentation of an endogenous antigen.
33. + T cells in allogeneic mixed lymphocyte reactions. Their capacity to cross-present antigens on MHC class I molecules was not investigated.
34. 209-217(210M), is considerably more immunogenic because it remains long enough at the APC surface to activate naïve T cells.
35. 26-35(27L). They found that many vaccine-induced CTLs are inefficient for tumor cell lysis, as opposed to CTLs resulting from a spontaneous response to the tumor and directed against the natural peptides.
36. + T cells from melanoma patients reveals inefficient antigen processing Eur J Immunol 31 2001 2642 2651
37. M.R. Parkhurst, J.P. Riley, T. Igarashi, Y. Li, P.F. Robbins, and S.A. Rosenberg Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase Clin Cancer Res 10 2004 4688 4698
38. + T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients Proc Natl Acad Sci USA 99 2002 11813 11818
39. •], these findings underline the crucial role of reduced lysosomal proteolysis for cross-presentation. The effect of chloroquine was then investigated in a human vaccination setting with healthy individuals who had responded to an anti-hepatitis B virus vaccine 8-10 years earlier. A new injection of the recombinant protein vaccine with chloroquine per os induced a substantial CD8+ T cell response to hepatitis B virus in six of nine individuals, whereas no response was found in the eight individuals who did not receive chloroquine.
40. P.J. Tacken, I.J. de Vries, K. Gijzen, B. Joosten, D. Wu, R.P. Rother, S.J. Faas, C.J. Punt, R. Torensma, and G.J. Adema Effective induction of naive and recall T cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody Blood 106 2005 1278 1285
41. V. Ramakrishna, J.F. Treml, L. Vitale, J.E. Connolly, T. O'Neill, P.A. Smith, C.L. Jones, L-Z. He, J. Goldstein, and P.K. Wallace Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules J Immunol 172 2004 2845 2852
42. A. Heit, K.M. Huster, F. Schmitz, M. Schiemann, D.H. Busch, and H. Wagner CpG-DNA aided cross-priming by cross-presenting B cells J Immunol 172 2004 1501 1507
43. A. Heit, T. Maurer, H. Hochrein, S. Bauer, K.M. Huster, D.H. Busch, and H. Wagner Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells J Immunol 170 2003 2802 2805
44. M. Schnurr, Q. Chen, A. Shin, W. Chen, T. Toy, C. Jenderek, S. Green, L. Miloradovic, D. Drane, and I.D. Davis Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery Blood 105 2005 2465 2472
45. A. Macagno, M. Gilliet, F. Sallusto, A. Lanzavecchia, F.O. Nestle, and M. Groettrup Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation Eur J Immunol 29 1999 4037 4042
46. A. Macagno, L. Kuehn, R. de Giuli, and M. Groettrup Pronounced up-regulation of the PA28alpha/beta proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation Eur J Immunol 31 2001 3271 3280
47. S. Morel, F. Lévy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A-L. Peitrequin, B. Monsarrat, R. Van Velthoven, J.-C. Cerottini, and T. Boon Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells Immunity 12 2000 107 117
48. E.S. Schultz, J. Chapiro, C. Lurquin, S. Claverol, O. Burlet-Schiltz, G. Warnier, V. Russo, S. Morel, F. Levy, and T. Boon The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome J Exp Med 195 2002 391 399
49. B.J. Van den Eynde, and S. Morel Differential processing of class-1-restricted epitopes by the standard proteasome and the immunoproteasome Curr Opin Immunol 13 2001 147 153
50. Q.-M. Wang, S.-H. Sun, Z.-L. Hu, F.-J. Zhou, M. Yin, C.-J. Xiao, and J.-C. Zhang Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine Scand J Immunol 60 2004 219 225
51. S.B.J. Wong, C.B. Buck, X. Shen, and R.F. Siliciano An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses J Immunol 173 2004 3073 3083
52. S. Sanderson, K. Frauwirth, and N. Shastri Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins Proc Natl Acad Sci USA 92 1995 7217 7221
53. Z. Su, J. Dannull, B.K. Yang, P. Dahm, D. Coleman, D. Yancey, S. Sichi, D. Niedzwiecki, D. Boczkowski, and E. Gilboa Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer J Immunol 174 2005 3798 3807
54. A. Bonehill, C. Heirman, S. Tuyaerts, A. Michiels, K. Breckpot, F. Brasseur, Y. Zhang, P. van der Bruggen, and K. Thielemans Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules J Immunol 172 2004 6649 6657
55. T. Doan, K. Herd, I. Ramshaw, S. Thomson, and R.W. Tindle A polytope DNA vaccine elicits multiple effector and memory CTL responses and protects against human papillomavirus 16 E7-expressing tumour Cancer Immunol Immunother 54 2005 157 171
56. M.J. Palmowski, E.M. Choi, I.F. Hermans, S.C. Gilbert, J.L. Chen, U. Gileadi, M. Salio, A. Van Pel, S. Man, and E. Bonin Competition between CTL narrows the immune response induced by prime-boost vaccination protocols J Immunol 168 2002 4391 4398
57. A.L. Ackerman, C. Kyritsis, R. Tampe, and P. Cresswell Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens Proc Natl Acad Sci USA 100 2003 12889 12894